• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Apogee Therapeutics, Inc. - Common Stock (NQ:APGE)

    90.67 +6.48 (+7.69%)
    Streaming Delayed Price Updated: 3:41 PM EDT, Jun 4, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 980,937
    Open 84.00
    Bid (Size) 90.55 (100)
    Ask (Size) 90.78 (900)
    Prev. Close 84.19
    Today's Range 84.00 - 91.13
    52wk Range 34.34 - 95.30
    Shares Outstanding 56,367,802
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Apogee Therapeutics Readies Zumi for Phase 3 With Blackstone Backing ↗
    Apogee Therapeutics (NASDAQ:APGE) executives said the company is preparing to move its lead drug candidate, zumilokibart, into Phase 3 testing later this year after reporting Phase 2b data in atopic... 
    Via MarketBeat
    Topics Initial Public Offering
    News headline image
    Apogee Therapeutics to Participate in Upcoming June Conferences
    From Apogee Therapeutics
    Via GlobeNewswire

    Performance

    YTD
    +19.6%
    +19.6%
    1 Month
    +8.5%
    +8.5%
    3 Month
    +25.4%
    +25.4%
    6 Month
    +21.6%
    +21.6%
    1 Year
    +144.5%
    +144.5%

    More News

    Read More
    News headline image
    Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart
    From Apogee Therapeutics
    Via GlobeNewswire
    News headline image
    Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis
    From Apogee Therapeutics
    Via GlobeNewswire
    Apogee Therapeutics (NASDAQ:APGE) Beats Q1 Estimates with Strong Cash Runway and Promising Clinical Progress ↗
    Via Chartmill
    Apogee Therapeutics (NASDAQ:APGE) Reports Q4 2025 Results, Highlights Cash Runway and Key 2026 Clinical Catalysts ↗
    Via Chartmill
    News headline image
    Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026
    From Apogee Therapeutics
    Via GlobeNewswire
    News headline image
    Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results
    From Apogee Therapeutics
    Via GlobeNewswire
    News headline image
    Eli Lilly Shares Slip Despite Positive Eczema Trial Results: Why the Market Reacted Coolly
    Via MarketMinute
    News headline image
    Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million
    From Apogee Therapeutics
    Via GlobeNewswire
    News headline image
    Apogee CEO Sells 20,000 Shares as Stock Surges Nearly 100% in a Year, but Here's What Really Matters for Investors ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering
    From Apogee Therapeutics
    Via GlobeNewswire
    News headline image
    Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering
    From Apogee Therapeutics
    Via GlobeNewswire
    News headline image
    Small-Cap Resilience: Russell 2000 Surges 3% as Geopolitical Tensions Ease and ‘Risk-On’ Appetite Returns
    Via MarketMinute
    Topics ETFs Economy Stocks
    Gapping stocks in Monday's session ↗
    Via Chartmill
    Wondering what's happening in today's pre-market session? ↗
    Via Chartmill
    News headline image
    Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis
    From Apogee Therapeutics
    Via GlobeNewswire
    News headline image
    Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026
    From Apogee Therapeutics
    Via GlobeNewswire
    News headline image
    Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools ↗
    Via The Motley Fool
    News headline image
    What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    VR Adviser Adds Over 1 Million Savara Shares ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results
    From Apogee Therapeutics
    Via GlobeNewswire
    News headline image
    Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance

    Frequently Asked Questions

    Is Apogee Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Apogee Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Apogee Therapeutics, Inc. - Common Stock trade on?
    Apogee Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Apogee Therapeutics, Inc. - Common Stock?
    The ticker symbol for Apogee Therapeutics, Inc. - Common Stock is APGE on the Nasdaq Stock Market
    What is the current price of Apogee Therapeutics, Inc. - Common Stock?
    The current price of Apogee Therapeutics, Inc. - Common Stock is 90.67
    When was Apogee Therapeutics, Inc. - Common Stock last traded?
    The last trade of Apogee Therapeutics, Inc. - Common Stock was at 06/04/26 03:41 PM ET
    What is the market capitalization of Apogee Therapeutics, Inc. - Common Stock?
    The market capitalization of Apogee Therapeutics, Inc. - Common Stock is 5.11B
    How many shares of Apogee Therapeutics, Inc. - Common Stock are outstanding?
    Apogee Therapeutics, Inc. - Common Stock has 5B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.